Prostate Cancer Clinical Trials in Phoenix

Showing 101-120 of 219 trials

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

NCT05488548

A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies

Castrate Resistant Prostate CancerNUT CarcinomaChronic Myelomonocytic Leukemia+1 more

Epigenetix, Inc.75 participantsStarted Dec 2022

Phoenix, Arizona, United States • Jacksonville, Florida, United States • Boston, Massachusetts, United States +3 more locations

COMPLETED< 1 mile

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

NCT02380274

The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management. This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.

Prostate CancerCastration-resistant Prostate CancerMetastatic Prostate Cancer

Astellas Pharma Global Development, Inc.1,030 participantsStarted Mar 2015

Homewood, Alabama, United States • Anchorage, Alaska, United States • Phoenix, Arizona, United States +145 more locations

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

Prostate Cancer Trials in Other Cities

A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients with Prostate Cancer

Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer

ART-Pro: Clinical Trial Evaluating Biparametric MRI and Advanced, Quantitative Diffusion MRI for Detection of Prostate Cancer

Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

Stockholm3 Validation Study in a Multi-Ethnic Cohort

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer

Other Conditions in Phoenix